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 College oAbstract Background and purpose: One of the main drawbacks in the management of patients
with traumatic brain injuries (TBI) is the absence of a widely available and rapid diagnostic test.
The objective of our study was to assess whether Phosphorylated Neuroﬁlament H (pNF-H) might
provide useful diagnostic information as an indication of axonal injury in the early evaluation of
such patients and whether levels of the pNF-H correlated with different clinical variables.
Methods: A total of 30 patients presenting to the critical care department of Cairo University
diagnosed with traumatic brain injury were prospectively studied. Blood samples for pNF-H were
assayed on admission and after 7 days. Neuroﬁlament levels correlated with Glasgow coma scale
and CT ﬁndings on admission and after 7 days. Rankin score at 3 months was used to detect the
degree of disability.
Results: Phosphorylated Neuroﬁlament H levels showed a negative correlation with GCS on
admission and after 7 days in traumatic brain injury; hence higher neuromarker levels were associ-
ated with lower GCS on admission and after 7 days. There was a negative correlation between neu-
roﬁlament levels and Marshal CT scores on admission and after 7 days (r= 0.56.0.4) hence higher
neuroﬁlament levels correlated with worse CT ﬁndings. Patients who died or had the greatest Ran-
kin 6 and 5 after 3 months had the highest levels of pNF-H on admission and after 7 days. The cut
off level of pNF-H to detect death and disability was 35 pg/ml on admission (sensitivity 82%,2093839.
(M.O. Ghonemi).
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140 M.O. Ghonemi et al.speciﬁcity 78%) and was 11 pg/ml after 7 days (sensitivity87%, and speciﬁcity 92%).
Conclusion: Phosphorylated Neuroﬁlament H can be used as a diagnostic and prognostic marker
in patients with TBI as seen by the presence of signiﬁcant correlations between the marker levels
and different clinical and radiological tools.
Open access under CC BY-NC-ND license.
© 2013 The Egyptian College of Critical Care Physicians. Production and hosting by Elsevier B.V.Introduction
Following CNS injury, certain proteins are released from neu-
rons. Many studies have identiﬁed such proteins like S-100
protein, Glial Fibrillary Acidic Protein (GFAP) and Neuron
speciﬁc enolase (NSE). However none of those markers have
shown strong correlations with clinical and radiological ﬁnd-
ings in patients with TBI. There has been a growing apprecia-
tion that many kinds of CNS injury and disease states are the
result of axonal injury and degeneration [1,2]. Accordingly, a
convenient method of detecting ongoing axonal loss might
be particularly useful experimentally and clinically. The perfect
marker to detect axonal injury should have several properties;
it should be speciﬁc to axons, it should be profuse enough so
that it can be readily detectable after the signiﬁcant dilution
that occurs following release into blood, and it should be resis-
tant to proteases so that it is not broken down prior to or fol-
lowing release.
Over the last years, many strides have been taken in the
characterization of Neuroﬁlament proteins and their func-
tions. Early studies by Hsieh et al. have shown that phosphor-
ylation of neuroﬁlaments is required for the proper functions
of axons by regulating axon diameter [21]. The Neuroﬁlament
H (pNF-H) protein sequence contains unusual tandemly re-
peated 6–8-amino-acid sequences centered on the sequence ly-
sine-serine-proline. The serine residues are phosphorylated [3]
and are axon speciﬁc [4]. This phosphorylated form of NF-H
(here referred to as pNF-H) is known to be more resistant to
calpain and other proteases [5,6] Also, pNF-H is highly immu-
nogenic, and the multiple repeated phosphorylated sites are an
excellent target for antibody-based assays. Taken together,
these facts suggest that pNF-H might be a good candidate
for a biomarker of axonal injury.
Patients and methods
Study design
This is a randomized study that was prospectively conducted
on 30 patients with TBI presenting to the Critical Care Depart-
ment Cairo university Hospitals in the period from January
2010 to January 2011. Informed written consents had been ob-
tained from the relatives and the study was approved by the
Hospital’s Ethics Committee.
Inclusion criteria
Thirty patients with isolated traumatic brain injury deﬁned
according to the Head Injury Interdisciplinary Special Interest
Group of the American Congress of Rehabilitation Medicine
[16] by having at least one of the following: any period of loss
of consciousness, any loss of memory for events immediatelybefore or after the trauma, any alteration in mental state at
the time of the accident focal neurologic deﬁcits which may
or may not be transient, and abnormal CT scan ﬁndings.
Exclusion criteria
The following patients were excluded:
 Patients with chronic neurological disease
 Patients with seizure activity
 Patients with renal impairment
 Patients with Multi-organ Failure Syndrome
 Patients with Multiple trauma
 Patients younger than 18 years and older than 65 years
 Patients who were receiving or those candidates for throm-
bolytic therapy.
Methods
 Full history taking from the patients, relatives or witnesses
with stress on the onset of neurological symptoms.
 Complete general and focused neurological examination.
 Blood samples were taken for routine labs and for pNF-H
levels. Samples were taken within the ﬁrst 24 h (pNF-H1)
and after 7 days (pNF-H2).
 For each patient a non-contrast CT brain (NCCT) was
done on admission and after 7 days. Image review was inde-
pendently performed on a workstation radiologists or neu-
rologists. Marshall CT score was used to assess CT ﬁndings
on admission (MARSHALL1) and after 7 days
(MARSHALL2).
 Glasgow coma scale was calculated on admission (GCS1)
and repeated after 7 days (GCS2).
Outcome analysis: Rankin score
Rankin score was used to assess patients’ outcome after an
interval of 3 months. Each patient was given a number from
1 to 6 according to the level of disability as shown in Table 1
[19].
Neuroﬁlament H assay method
Blood samples were drawn from each patient on admission
and after 7 days. The BioVendor Human Phosphorylated Neu-
roﬁlament H ELISA, standards, quality controls and samples
were placed and left in microplate wells that contained chicken
polyclonal anti-pNF-H antibody. One hour later, detection
rabbit polyclonal anti-pNF-H antibody was added and incu-
Table 1 Rankin Score.
6 = Death
5 = Severe disability. Bedridden, incontinent, and requiring constant nursing care and attention
4 =Moderately severe disability Unable to walk without assistance, and unable to attend to own bodily needs without assistance
3 =Moderate disability; Requiring some help, but able to walk without assistance
2 = Slight disability Unable to carry out all previous activities but able to look after own aﬀairs without assistance
1 = No signiﬁcant disability Able to carry out all usual duties and activities
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ing, horseradish peroxidase conjugated antibody against rabbit
antibody was added. After 60 min incubation and the last
washing step, the remaining conjugate was allowed to react
with the substrate solution. The reaction was stopped by addi-
tion of acidic solution and absorbance of the resulting yellow
product was measured.Figure 1 Relationship between Rankin Score after 3 months and
Neuroﬁlament levels in the study population.Data analysis
Pearson correlation analysis of data was performed using
Statistical Package for the Social Sciences (SPSS) software.
The association of subject characteristics to pNF-H levels
was studied with multiple regressions. The pNF-H data were
square root transformed to effect normality of distribution of
residuals. Relationships between the square roots of pNF-H
were investigated within groups with Pearson correlation
and the two-sample t-test. Analysis of correlation was used
to assess the different relationships between pNF-H and
other variables.Results
The study of demographic characteristics of the patients
groups showed that the mean age of patients in the groups
studied was 36.5 with a range of 19–55 years. There was a total
of 17 male patients and 13 females.
Mean Neuroﬁlament H levels in the study group
The mean Neuroﬁlament level on admission (pNF-H1) was
47 ± 25.8 pg/ml in Group A and the mean Neuroﬁlament H
level after 7 days (pNF-H2) was 148 ± 90.3 pg/ml i.e. the Neu-
roﬁlament level was signiﬁcantly higher after 7 days
(p< 0.005).
Analysis of outcome: Rankin score
There was an apparent increase in mean Neuroﬁlament lev-
els in patients with the greatest disability (Rankin 5) and
those who died (Rankin 6). Patients with the least disability
(Rankin 1 and 2) showed the lowest mean Neuroﬁlament
levels on admission and after 7 days. Patients with higher
levels of Neuroﬁlament H on admission and after 7 days
showed a greater Rankin score after 3 months and hence a
greater disability (p< 0.005). Hence Neuroﬁlament H levels
were signiﬁcantly higher in patients with poor outcome
(Fig. 1).Receiver-operating characteristic (ROC) curves showing
discriminative abilities of Neuroﬁlament H for predicting
outcome after 3 months
On admission
On admission, the ROC curve showed cut-off point of 35 pg/
ml for pN-FH level to predict severe disability or death with
sensitivity 82.1% and speciﬁcity 78.4%, positive predictive va-
lue 74.4% and negative predictive value 14.9% with Area Un-
der Curve (AUC 87.1%). Hence patients with Neuroﬁlament
H levels of 35 pg/ml or more on admission had a worse Rankin
score after 3 months (Fig. 2).
After 7 days
One week later, the ROC curve showed cut-off point of
111 pg/ml for pNF-H to predict severe disability or death with
sensitivity 87.2% and speciﬁcity 92.2%, positive predictive va-
lue 89.5% and negative predictive value 9.6% with Area Un-
der Curve (AUC 95.7%). Hence patients with Neuroﬁlament
H levels of more than 111 pg/ml after 7 days had a worse Ran-
kin score after 7 days (Fig. 3).Correlation between GCS and Neuroﬁlament H levels
As shown by the scatter diagram there was a strong nega-
tive correlation between the level of Neuroﬁlament H and
the Glasgow Coma Scale in patients with traumatic brain
injury on admission (r= 0.66 with a p< 0.005). This ap-
plies also after 7 days (r= 0.78, p< 0.005). In other
words, the higher pNF-H levels correlated with lower GCS
(Fig. 4).
Figure 2 ROC curve on admission.
Figure 3 ROC curve after one week.
Figure 4 Correlation between pNFH and GCS.
Figure 5 Mean MARSHALL scores.
Figure 6 Correlation between pNF-H and MARSHALL.
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The mean marshal score in group A was 2.1 on admission
(Marshal1), and was 3.7 after 7 days (Marshal2) (Fig. 5).
6- Correlation between Neuroﬁlament H and Marshall score
There was a signiﬁcant positive correlation of 0.56 between the
mean Marshal score and the mean Neuroﬁlament H level both
on admission and after 7 days (r= .56.0.4 p< 0.005) In
other words, the higher the level of Neuroﬁlament the higher
the Marshal score (Fig. 6).Discussion
One of the main problems in patients with TBI is the absence
of a blood marker that can be collected easily to aid in diagno-
sis and follow up of these patients. Numerous scientists have
studied various proteins for this purpose but results were not
promising.
The best example for a diagnostic and prognostic marker is
the cardiac troponin test. Development of techniques to detect
the cardiac isoenzymes of troponin with high sensitivity led to
the ultimate revision of the clinical deﬁnition of myocardial
infarction to elevate the role of biomarkers in diagnosis. The
main property of the troponin test that led to its widespread
use was a nearly absolute speciﬁcity for myocardial tissue (un-
like creatine kinase), as well as high sensitivity. A biomarker
with similar properties to detect acute brain insults would be
of great use [22].
Phosphorylated Neuroﬁlament H (pNF-H) is a large pro-
tein with a molecular weight of 190–210 kD depending on
the degree of phosphorylation. Following neuro-axonal injury
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be measured using ELISA. From the extracellular ﬂuid it dif-
fuses into the CSF compartment. From the CSF, pNF-H
reaches the blood via the blood CSF barrier at the lumbar level
or it may diffuse directly through the cortical arachnoid villi to
the blood stream [20].
In this study, we have demonstrated that pNF-H can be de-
tected in the blood of patients with traumatic brain injuries.
The presence of Neuroﬁlaments in blood indicated damage
of neurons after such injuries. The importance of pNF-H lies
in the fact that it could be detected in the blood of TBI pa-
tients, which makes such marker a convenient and simple indi-
cator of brain damage, in contrast to other markers measured
in the CSF. Blood collection is more practical and safer than
CSF sampling suggesting that analysis of blood for pNF-H
could be a useful clinical tool to conveniently assess axonal
damage.
Recent data have emphasized that the morphology of ver-
tebrate neurons renders the axons sensitive to mechanical
and metabolic damage and a major portion of the pathophys-
iology following brain injury is due to axonal damage [1].
Therefore, a convenient blood assay of axonal loss could be
of great utility.
Our data showed negative correlation between the GCS
and pNF-H levels both on admission and after 7 days. pNF-
H levels also correlated with CT ﬁndings. In traumatic brain
injury patients, levels showed an inverse relationship with
MARSHAL CT scores.
Rankin score was used to assess outcome after 3 months.
Patients with higher levels of Neuroﬁlament H on admission
and after 7 days showed a greater Rankin score after 3 months
and hence a greater disability (p< 0.005). There was an
apparent increase in mean Neuroﬁlament levels in patients
with the greatest disability (Rankin 5,) and those who died
(Rankin 6,). Patients with the least disability (Rankin 1 and
2) showed the lowest mean Neuroﬁlament levels on admission
and after 7 days. Hence Neuroﬁlament H levels were signiﬁ-
cantly higher in patients with poor outcome. ROC curve
showed cut-off point for NFH level at admission to predict se-
vere disability or death was 35 pg/ml and 111 pg/ml after
7 days.
Several other proteins have been proposed as
potential biomarkers in TBI [9] For example, the small
Ca2+-binding modulator protein S-100b has been extensively
studied in both animal models of TBI and human TBI vic-
tims [9]. While S-100b has been shown to be elevated follow-
ing TBI in humans, its speciﬁcity to brain injury was
debated since it appears to be elevated in humans with other
forms of trauma not related to the brain. In addition, S-
100b levels have been shown to be elevated following femo-
ral fractures without any accompanying brain injury [10]
and are elevated in long distance runners [11]. Although
pNF-H was elevated post traumatic brain injury in our
study and correlated with the level of consciousness and
CT ﬁndings, we still do not have any data about other
causes that will increase neuroﬁlaments in blood and
whether our marker – pNF-H – is more speciﬁc to axonal
damage than other markers.
However, patients included in our study suffered only trau-
ma to the head, and patients with multiple trauma or those
with multiorgan dysfunction were excluded. Thus further stud-
ies may be needed to assess the degree of speciﬁcity of pNF-H.Previous studies have also examined serum levels of
Cleaved tau protein (c-tau) as a marker of TBI in both humans
and animal models. However, the level of c-tau in the serum of
injured humans and animals is signiﬁcantly less than pNF-H.
Furthermore, tau is not neuronal speciﬁc; it is expressed in
nonneuronal tissues such as the heart, skeletal muscle, lung,
kidney, and testis [7,12]. Again further studies will be required
before we understand if similar problems will occur with the
use of pNFH protein as a biomarker and if it will be elevated
in other non neurological conditions.
Interestingly, Anderson J studied Neuroﬁlaments in rats
subjected to different forms of cortical contusion and were
stratiﬁed according to the degree of trauma into moderate
and severe cortical contusions. The level of serum Neuroﬁla-
ments detected correlated with the severity of the brain injury.
The peak of Neuroﬁlaments was seen at 2 days post-injury in
all groups, with the severe injury group showing the highest
amounts of pNF-H. He stated that ‘‘It will be of interest to
compare the results obtained here on rats with the results of cor-
tical injury on larger mammals and humans. Larger mammals
have much thicker and usually folded cortices containing a great-
er proportion of white matter that is expected to be rich in Neu-
roﬁlaments containing axons. In fact, about 42% of the human
neocortex is white matter compared to less than 10% in the
rat and other small lissencephalic mammal’’ [23]. Our study re-
sults can be used to complement such results showing the Neu-
roﬁlaments can be detected in humans suffering from different
forms of TBI and can be correlated with various clinical and
radiological markers.
As mentioned above, if pNF-H is located solely in axons,
axonal loss is a major problem in many kinds of human neu-
rological damage and disease states, such as TBI, multiple scle-
rosis, and amyotrophic lateral sclerosis [1]. This can be
problematic in patients with chronic CNS disease. However,
in our study, we excluded patients with any neurological disor-
ders other than traumatic brain injury thus we can say that in-
crease in levels of pNF-H in our population was solely due to
acute brain injury and not due to chronic CNS diseases.
Conclusion
Blood levels of pNF-H were quantiﬁable in patients with trau-
matic brain injury on admission to the ICU and after 7 days.
The blood levels were signiﬁcantly higher levels in patients
with poor outcome as compared with those with good out-
come in the ﬁrst 3 months following TBI. Phosphorylated
Neuroﬁlaments levels showed signiﬁcant correlations with
the level of consciousness and CT ﬁndings in such patients.
Further studies will be needed to complement our results in
larger patients’ samples and more importantly to elucidate
other non cranial causes of increased pNF-H level in serum.
A more detailed study of the pattern of rise and decline of
pNF-H in patients with traumatic brain injury will be comple-
mentary to our study. Thus it is too early to recommend the
routine use of plasma pNF-H in this context for clinical deci-
sion-making.
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